Comparative effectiveness of the bivalent BA.4-5 and BA.1 mRNA-booster vaccines in the Nordic countries
Niklas Worm Andersson, Emilia Myrup Thiesson, Ulrike Baum, Nicklas Pihlström, Jostein Starrfelt, Kristýna Faksová, View ORCID ProfileEero Poukka, Hinta Meijerink, Rickard Ljung, View ORCID ProfileAnders Hviid
doi: https://doi.org/10.1101/2023.01.19.23284764
Niklas Worm Andersson
1Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark
MDEmilia Myrup Thiesson
1Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark
MScUlrike Baum
2Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare, Mannerheimintie 166, 00300 Helsinki, Finland
PhDNicklas Pihlström
3Division of Licensing, Swedish Medical Products Agency, Dag Hammarskjölds väg 42, 751 03 Uppsala, Sweden
MScJostein Starrfelt
4Department of Infection Control and Preparedness, Norwegian Institute of Public Health, Lovisenberggata 8, 0456 Oslo, Norway
PhDKristýna Faksová
1Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark
MScEero Poukka
2Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare, Mannerheimintie 166, 00300 Helsinki, Finland
5Department of Public Health, Faculty of Medicine, University of Helsinki, Yliopistonkatu 4, 00100 Helsinki, Finland
MDHinta Meijerink
6Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Lovisenberggata 8, 0456 Oslo, Norway
PhDRickard Ljung
7Division of Use and Information, Swedish Medical Products Agency, Dag Hammarskjölds väg 42, 751 03 Uppsala, Sweden
8Institute of Environmental Medicine, Karolinska Institutet, Nobels väg 13, 171 77 Stockholm, Sweden
MDAnders Hviid
1Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark
9Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen Ø, Denmark
DMSc
Posted January 19, 2023.
Comparative effectiveness of the bivalent BA.4-5 and BA.1 mRNA-booster vaccines in the Nordic countries
Niklas Worm Andersson, Emilia Myrup Thiesson, Ulrike Baum, Nicklas Pihlström, Jostein Starrfelt, Kristýna Faksová, Eero Poukka, Hinta Meijerink, Rickard Ljung, Anders Hviid
medRxiv 2023.01.19.23284764; doi: https://doi.org/10.1101/2023.01.19.23284764
Comparative effectiveness of the bivalent BA.4-5 and BA.1 mRNA-booster vaccines in the Nordic countries
Niklas Worm Andersson, Emilia Myrup Thiesson, Ulrike Baum, Nicklas Pihlström, Jostein Starrfelt, Kristýna Faksová, Eero Poukka, Hinta Meijerink, Rickard Ljung, Anders Hviid
medRxiv 2023.01.19.23284764; doi: https://doi.org/10.1101/2023.01.19.23284764
Subject Area
Subject Areas
- Addiction Medicine (403)
- Allergy and Immunology (712)
- Anesthesia (207)
- Cardiovascular Medicine (2969)
- Dermatology (253)
- Emergency Medicine (445)
- Epidemiology (12807)
- Forensic Medicine (12)
- Gastroenterology (830)
- Genetic and Genomic Medicine (4621)
- Geriatric Medicine (423)
- Health Economics (732)
- Health Informatics (2941)
- Health Policy (1073)
- Hematology (393)
- HIV/AIDS (932)
- Medical Education (430)
- Medical Ethics (116)
- Nephrology (475)
- Neurology (4408)
- Nursing (238)
- Nutrition (649)
- Oncology (2295)
- Ophthalmology (652)
- Orthopedics (260)
- Otolaryngology (327)
- Pain Medicine (281)
- Palliative Medicine (84)
- Pathology (502)
- Pediatrics (1200)
- Primary Care Research (502)
- Public and Global Health (7004)
- Radiology and Imaging (1544)
- Respiratory Medicine (921)
- Rheumatology (444)
- Sports Medicine (386)
- Surgery (491)
- Toxicology (60)
- Transplantation (212)
- Urology (182)